Increased ERK and JNK activities correlate with disease activity in patients with systemic lupus erythematosus

Annals of the Rheumatic Diseases

Volumn 69, Issue 1, 2010, Pages 175-180

  Molad, Y ^a   Amit Vasina, M ^b   Bloch, O ^b   Yona, E ^b   Rapoport, M J ^b  

^a RABIN MEDICAL CENTER   (Israel)

^b ASSAF HAROFEH MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE; STRESS ACTIVATED PROTEIN KINASE;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CELL LYSATE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE SEVERITY; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN CELL; MALE; OUTPATIENT; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; SCORING SYSTEM; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC LUPUS ERYTHEMATOSUS DISEASE ACTIVITY INDEX;

ADULT; AGED; BIOLOGICAL MARKERS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MAP KINASE KINASE 4; MIDDLE AGED; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX;

EID: 73449141813     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/ard.2008.102780     Document Type: Article

References (20)

1. Downward J, Graves JD, Warne PH, et al. Stimulation of p21ras upon T-cell activation. Nature 1990;346:719-23.
2. Mok CC, Lau CS. Pathogenesis of system lupus erythematosus. J Clin Pathol 2003;56:481-90.
3. Rapoport MJ, Mor A, Amit M, et al. Decreased expression of the p21ras stimulatory factor hSOS in PBMC from inactive SLE patients. Lupus 1999;8:24-8.
4. Rapoport MJ, Amit M, Aharoni D, et al. Constitutive up-regulated activity of MAP kinase is associated with down-regulated early p21Ras pathway in lymphocytes of SLE patients. J Autoimmun 2002;9:63-70.
5. Rapoport MJ, Sharabi A, Aharoni D, et al. Amelioration of SLE-like manifestations in (NZBxNZW)F1 mice following treatment with a peptide based on the complementarity determining region 1 of an autoantibody is associated with a down-regulation of apoptosis and of the pro-apoptotic factor JNK kinase. Clin Immunol 2005;117:262-70.
6. Cedeno S, Cifarelli DF, Blasini AM, et al. Defective activity of ERK-1 and ERK-2 mitogen-activated protein kinases in peripheral blood T lymphocytes from patients with systemic lupus erythematosus: potential role of altered coupling Ras guanine nucleotide exchange factor hSos to adapter protein Grb2 in lupus T cells. Clin Immunol 2003;106:41-9.
7. Deng C, Lu Q, Zhang Z, et al. Hydralazine may induce autoimmunity by inhibiting extracellular signal-regulated kinase pathway signaling. Arthritis Rheum 2003;48:746-56.
8. Gladman DD, Ibañez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol 2002;29:288-91.
9. Petri M, Buyon J, Kim M. Classification and definition of major flares in SLE clinical trials. Lupus 1999;8:685-91.
10. Dixon WJ (chief editor). BMDP statistical software. Los Angeles, California: University of California Press, 1993.
11. Zhong XP, Hainey EA, Olenchock BA, et al. Regulation of T cell receptor induced activation of the Ras-ERK pathway by diacylglycerol kinase zeta. J Biol Chem 2002;277:31089-98.
12. Jacob A, Cooney D, Pradhan M, et al. Convergence of signaling pathways on the activation of ERK in B cells. J Biol Chem 2002;277:23420-6.
13. Swan KA, Alberola-Ila J, Cross JA, et al. Involvement of p21Ras distinguished positive and negative selection in thymocytes. EMBO J 1995;14:276-85.
14. Takahashi Y, Inamine A, Hashimoto S, et al. Novel Role of the Ras cascade in memory B cell response. Immunity 2005;23:127- 38.
15. Yamashita M, Kimura M, Kubo M, et al. T cell antigen receptor-mediated activation of the Ras/mitogen-activated protein kinase pathway controls interleukin 4 receptor function and type-2 helper T cell differentiation. Proc Natl Acad Sci USA 1999;96:1024-9.
16. Genot E, Cantrell DA. Ras regulation and function in lymphocytes. Curr Opin Immunol 2000;12:289-94.
17. Ricón M, Flavell RA, Davis RJ. Signal transduction by MAP kinases in T lymphocytes. Oncogene 2001;20:2490-7.
18. Illei GG, Tackey E, Lapteva L, et al. Biomarkers in systemic lupus erythematosus. II. Markers of disease activity. Arthritis Rheum 2004;50:2048-65.
19. Kuan CY, Burke RE. Targeting the JNK signaling pathway for stroke and Parkinson's diseases therapy. Curr Drug Targets CNS Neurol Disord 2005;4:63-7.
20. English JM, Cobb MH. Pharmacological inhibitors of MAPK Pathways. Trends Pharmacol Sci 2002;23:40-5.